Hypogammaglobulinemia and Risk of Exacerbation and Mortality in Patients with COPD

References

• LozanoR, NaghaviM, ForemanK, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-023245604
   PubMed Web of Science ®Google Scholar
• RabeKF, HurdS, AnzuetoA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555. doi:10.1164/rccm.200703-456SO17507545
   PubMed Web of Science ®Google Scholar
• VestboJ, HurdSS, AgustiAG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi:10.1164/rccm.201204-0596PP22878278
   PubMed Web of Science ®Google Scholar
• LangeP, MarottJL, VestboJ, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–981. doi:10.1164/rccm.201207-1299OC22997207
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):3. doi:10.1183/13993003.00214-2017
   Web of Science ®Google Scholar
• HanMK, AgustiA, CalverleyPM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604. doi:10.1164/rccm.200912-1843CC20522794
   PubMed Web of Science ®Google Scholar
• SniderGL. Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology. Am Rev Respir Dis. 1989;140(3 Pt 2):S3–8. doi:10.1164/ajrccm/140.3_Pt_2.S32675711
   PubMed Web of Science ®Google Scholar
• MiravitllesM, Soler-CatalunaJJ, CalleM, et al. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J. 2013;41(6):1252–1256. doi:10.1183/09031936.0011891223060631
   PubMed Web of Science ®Google Scholar
• HurstJR, VestboJ, AnzuetoA, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa090988320843247
   PubMed Web of Science ®Google Scholar
• BeehKM, GlaabT, StowasserS, et al. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res. 2013;14(1):116. doi:10.1186/1465-9921-14-11624168767
   PubMed Web of Science ®Google Scholar
• BafadhelM, McKennaS, TerryS, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671. doi:10.1164/rccm.201104-0597OC21680942
   PubMed Web of Science ®Google Scholar
• SchroederHW Jr., CavaciniL. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41–52. doi:10.1016/j.jaci.2009.09.04620176268
   PubMed Web of Science ®Google Scholar
• Leitao FilhoFS, Won RaS, MattmanA, et al. Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2017;140(4):1164–67 e6. doi:10.1016/j.jaci.2017.01.04628456620
   PubMed Web of Science ®Google Scholar
• McCullaghBN, ComellasAP, BallasZK, et al. Antibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD). PLoS One. 2017;12(2):e0172437. doi:10.1371/journal.pone.017243728212436
   PubMed Web of Science ®Google Scholar
• CowanJ, GaudetL, MulpuruS, et al. A retrospective longitudinal within-subject risk interval analysis of immunoglobulin treatment for recurrent acute exacerbation of chronic obstructive pulmonary disease. PLoS One. 2015;10(11):e0142205. doi:10.1371/journal.pone.014220526558756
   PubMed Web of Science ®Google Scholar
• ChristensenVL, RustoenT, CooperBA, et al. Distinct symptom experiences in subgroups of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1801–1809. doi:10.2147/COPD.S10529927536092
   PubMed Web of Science ®Google Scholar
• SanghaO, StuckiG, LiangMH, et al. The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49(2):156–163. doi:10.1002/art.1099312687505
   PubMed Web of Science ®Google Scholar
• JonesPW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19(3):398–404. doi:10.1183/09031936.02.0006370211936514
   PubMed Web of Science ®Google Scholar
• BestallJC, PaulEA, GarrodR, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.58110377201
   PubMed Web of Science ®Google Scholar
• QuanjerPH, TammelingGJ, CotesJE, et al. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16(Suppl 16):5–40. doi:10.1183/09041950.005s16938499054
   PubMedGoogle Scholar
• AabergeIS, SteinsvikTE, GroengEC, et al. Human antibody response to a pneumococcal vaccine in SCID-PBL-hu mice and simultaneously vaccinated human cell donors. Clin Exp Immunol. 1996;105(1):12–17. doi:10.1046/j.1365-2249.1996.d01-728.x8697618
   PubMed Web of Science ®Google Scholar
• YipNH, LedererDJ, KawutSM, et al. Immunoglobulin G levels before and after lung transplantation. Am J Respir Crit Care Med. 2006;173(8):917–921. doi:10.1164/rccm.200510-1609OC16399990
   PubMed Web of Science ®Google Scholar
• KlaustermeyerWB, GianosME, KuroharaML, et al. IgG subclass deficiency associated with corticosteroids in obstructive lung disease. Chest. 1992;102(4):1137–1142. doi:10.1378/chest.102.4.11371343817
   PubMed Web of Science ®Google Scholar
• CowanJ, MulpuruS, AlvarezG, et al. Chronic obstructive pulmonary disease exacerbation frequency and serum IgG levels. J Allergy Clin Immunol. 2018;141(2):830–831. doi:10.1016/j.jaci.2017.09.03629221818
   PubMed Web of Science ®Google Scholar
• Leitao FilhoFS, RaSW, MattmanA, et al. Reply. J Allergy Clin Immunol. 2018;141(2):831. doi:10.1016/j.jaci.2017.10.01329221816
   PubMed Web of Science ®Google Scholar
• PapiA, LuppiF, FrancoF, et al. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(3):245–251. doi:10.1513/pats.200512-125SF16636093
   PubMedGoogle Scholar
• DonaldsonGC, SeemungalTA, BhowmikA, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.84712324669
   PubMed Web of Science ®Google Scholar
• HoogendoornM, HoogenveenRT, Rutten-van MolkenMP, et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J. 2011;37(3):508–515. doi:10.1183/09031936.0004371020595157
   PubMed Web of Science ®Google Scholar
• SettipaneGA, PudupakkamRK, McGowanJH. Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol. 1978;62(3):162–166. doi:10.1016/0091-6749(78)90101-X681628
   PubMed Web of Science ®Google Scholar
• CalverleyPM, AndersonJA, CelliB, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• CrimC, CalverleyPM, AndersonJA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641–647. doi:10.1183/09031936.0019390819443528
   PubMed Web of Science ®Google Scholar
• KawanoT, MatsuseH, ObaseY, et al. Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone. Int Arch Allergy Immunol. 2002;128(3):240–243. doi:10.1159/00006425812119507
   PubMed Web of Science ®Google Scholar
• O’KeeffeS, GzelA, DruryR, et al. Immunoglobulin G subclasses and spirometry in patients with chronic obstructive pulmonary disease. Eur Respir J. 1991;4(8):932–936.1783083
   PubMed Web of Science ®Google Scholar
• BridgesRB, ChowCK, RehmSR. Micronutrient status and immune function in smokers. Ann N Y Acad Sci. 1990;587:218–231. doi:10.1111/j.1749-6632.1990.tb00149.x2113786
   PubMed Web of Science ®Google Scholar
• GulsvikA, FagerhoiMK. Smoking and immunoglobulin levels. Lancet. 1979;1(8113):449. doi:10.1016/S0140-6736(79)90934-6
   PubMed Web of Science ®Google Scholar
• QvarfordtI, RiiseGC, AnderssonBA, et al. IgG subclasses in smokers with chronic bronchitis and recurrent exacerbations. Thorax. 2001;56(6):445–449. doi:10.1136/thorax.56.6.44511359959
   PubMed Web of Science ®Google Scholar
• HaapanenN, MiilunpaloS, PasanenM, et al. Agreement between questionnaire data and medical records of chronic diseases in middle-aged and elderly Finnish men and women. Am J Epidemiol. 1997;145(8):762–769. doi:10.1093/aje/145.8.7629126003
   PubMed Web of Science ®Google Scholar
• LovaasKF, CooperJG, SandbergS, et al. Feasibility of using self-reported patient data in a national diabetes register. BMC Health Serv Res. 2015;15(1):553. doi:10.1186/s12913-015-1226-026666413
   PubMed Web of Science ®Google Scholar
• WeillD, BendenC, CorrisPA, et al. A consensus document for the selection of lung transplant candidates: 2014–an update from the pulmonary transplantation council of the international society for heart and lung transplantation. J Heart Lung Transplant. 2015;34(1):1–15. doi:10.1016/j.healun.2014.06.01425085497
   PubMed Web of Science ®Google Scholar